Literature DB >> 25440061

The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.

Cynthia Hong1, Stephanie M Marshall2, Allison L McDaniel2, Mark Graham3, Joseph D Layne4, Lei Cai4, Elena Scotti1, Rima Boyadjian1, Jason Kim5, Brian T Chamberlain6, Rajendra K Tangirala5, Michael E Jung6, Loren Fong7, Richard Lee3, Stephen G Young8, Ryan E Temel9, Peter Tontonoz10.   

Abstract

The LXR-regulated E3 ubiquitin ligase IDOL controls LDLR receptor stability independent of SREBP and PCSK9, but its relevance to plasma lipid levels is unknown. Here we demonstrate that the effects of the LXR-IDOL axis are both tissue and species specific. In mice, LXR agonist induces Idol transcript levels in peripheral tissues but not in liver, and does not change plasma LDL levels. Accordingly, Idol-deficient mice exhibit elevated LDLR protein levels in peripheral tissues, but not in the liver. By contrast, LXR activation in cynomolgus monkeys induces hepatic IDOL expression, reduces LDLR protein levels, and raises plasma LDL levels. Knockdown of IDOL in monkeys with an antisense oligonucleotide blunts the effect of LXR agonist on LDL levels. These results implicate IDOL as a modulator of plasma lipid levels in primates and support further investigation into IDOL inhibition as a potential strategy for LDL lowering in humans.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25440061      PMCID: PMC4261644          DOI: 10.1016/j.cmet.2014.10.001

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  27 in total

1.  Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.

Authors:  Jon L Collins; Adam M Fivush; Michael A Watson; Cristin M Galardi; Michael C Lewis; Linda B Moore; Derek J Parks; Joan G Wilson; Tim K Tippin; Jane G Binz; Kelli D Plunket; Daniel G Morgan; Elizabeth J Beaudet; Karl D Whitney; Steven A Kliewer; Timothy M Willson
Journal:  J Med Chem       Date:  2002-05-09       Impact factor: 7.446

2.  Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.

Authors:  Snehal U Naik; Xun Wang; Jaqueline S Da Silva; Michael Jaye; Colin H Macphee; Muredach P Reilly; Jeffrey T Billheimer; George H Rothblat; Daniel J Rader
Journal:  Circulation       Date:  2005-12-19       Impact factor: 29.690

Review 3.  The LXRs: a new class of oxysterol receptors.

Authors:  D J Peet; B A Janowski; D J Mangelsdorf
Journal:  Curr Opin Genet Dev       Date:  1998-10       Impact factor: 5.578

Review 4.  The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor.

Authors:  M S Brown; J L Goldstein
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

Review 5.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

6.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

Authors:  Jonathan Cohen; Alexander Pertsemlidis; Ingrid K Kotowski; Randall Graham; Christine Kim Garcia; Helen H Hobbs
Journal:  Nat Genet       Date:  2005-01-16       Impact factor: 38.330

7.  Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice.

Authors:  L B Agellon; A Walsh; T Hayek; P Moulin; X C Jiang; S A Shelanski; J L Breslow; A R Tall
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

8.  Autoregulation of the human liver X receptor alpha promoter.

Authors:  B A Laffitte; S B Joseph; R Walczak; L Pei; D C Wilpitz; J L Collins; P Tontonoz
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

9.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

10.  Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles.

Authors:  Aldo Grefhorst; Baukje M Elzinga; Peter J Voshol; Torsten Plösch; Tineke Kok; Vincent W Bloks; Fjodor H van der Sluijs; Louis M Havekes; Johannes A Romijn; Henkjan J Verkade; Folkert Kuipers
Journal:  J Biol Chem       Date:  2002-07-03       Impact factor: 5.157

View more
  36 in total

Review 1.  A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion.

Authors:  Ryan E Temel; J Mark Brown
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

2.  Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol.

Authors:  Salam Ibrahim; Suryanarayan Somanathan; Jeffrey Billheimer; James M Wilson; Daniel J Rader
Journal:  Cardiovasc Res       Date:  2016-01-19       Impact factor: 10.787

3.  Taurine-Mediated IDOL Contributes to Resolution of Streptococcus uberis Infection.

Authors:  Zhixin Wan; Riguo Lan; Yilin Zhou; Yuanyuan Xu; Zhenglei Wang; Zhenhua Luo; Jinfeng Miao
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

Review 4.  News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1.

Authors:  Bart van de Sluis; Melinde Wijers; Joachim Herz
Journal:  Curr Opin Lipidol       Date:  2017-06       Impact factor: 4.776

Review 5.  Liver X receptors in lipid signalling and membrane homeostasis.

Authors:  Bo Wang; Peter Tontonoz
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

6.  Phosphatidylinositol-(4,5)-Bisphosphate Regulates Plasma Cholesterol Through LDL (Low-Density Lipoprotein) Receptor Lysosomal Degradation.

Authors:  Yuanyuan Qin; Flora Ting; Mee J Kim; Jacob Strelnikov; Joseph Harmon; Feng Gao; Andrea Dose; Ba-Bie Teng; Mohsen Amir Alipour; Zemin Yao; Rosanne Crooke; Ronald M Krauss; Marisa W Medina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-19       Impact factor: 8.311

7.  A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes.

Authors:  Anke Loregger; Emma Claire Laura Cook; Jessica Kristin Nelson; Martina Moeton; Laura Jane Sharpe; Susanna Engberg; Madina Karimova; Gilles Lambert; Andrew John Brown; Noam Zelcer
Journal:  Mol Cell Biol       Date:  2015-11-02       Impact factor: 4.272

Review 8.  LXR Regulation of Brain Cholesterol: From Development to Disease.

Authors:  Rebecca Courtney; Gary E Landreth
Journal:  Trends Endocrinol Metab       Date:  2016-04-21       Impact factor: 12.015

9.  The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis.

Authors:  Jinkuk Choi; Jie Gao; Jaekwang Kim; Cynthia Hong; Jungsu Kim; Peter Tontonoz
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

10.  Idolizing the clearance of Amyloid-β by microglia.

Authors:  Nienke Marlies Van Loon; Noam Zelcer
Journal:  Ann Transl Med       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.